These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 19628161)

  • 21. NS5B RNA dependent RNA polymerase inhibitors: the promising approach to treat hepatitis C virus infections.
    Deore RR; Chern JW
    Curr Med Chem; 2010; 17(32):3806-26. PubMed ID: 20858218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nucleoside analog inhibitors of hepatitis C virus replication.
    Carroll SS; Olsen DB
    Infect Disord Drug Targets; 2006 Mar; 6(1):17-29. PubMed ID: 16787301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct-acting antivirals: the endgame for hepatitis C?
    D'Ambrosio R; Degasperi E; Colombo M; Aghemo A
    Curr Opin Virol; 2017 Jun; 24():31-37. PubMed ID: 28419938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection.
    Beaulieu PL
    Expert Opin Ther Pat; 2009 Feb; 19(2):145-64. PubMed ID: 19441916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.
    Berger KL; Sarrazin C; Nelson DR; Scherer J; Sha N; Marquis M; Côté-Martin A; Vinisko R; Stern JO; Mensa FJ; Kukolj G
    PLoS One; 2016; 11(8):e0160668. PubMed ID: 27494410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections.
    Beaulieu PL
    Curr Opin Investig Drugs; 2007 Aug; 8(8):614-34. PubMed ID: 17668364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of novel antiviral therapies for hepatitis C virus.
    Lin K
    Virol Sin; 2010 Aug; 25(4):246-66. PubMed ID: 20960299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Boceprevir, an NS3 protease inhibitor of HCV.
    Berman K; Kwo PY
    Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Telaprevir: hope on the horizon, getting closer.
    Weisberg IS; Jacobson IM
    Clin Liver Dis; 2009 Aug; 13(3):441-52. PubMed ID: 19628160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C.
    Welch NM; Jensen DM
    Liver Int; 2015 Jan; 35 Suppl 1():11-7. PubMed ID: 25529082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase.
    Koch U; Narjes F
    Infect Disord Drug Targets; 2006 Mar; 6(1):31-41. PubMed ID: 16787302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New antiviral therapies in the management of HCV infection.
    Farnik H; Zeuzem S
    Antivir Ther; 2012; 17(5):771-83. PubMed ID: 22626842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy.
    Sultanik P; Mallet V; Lagaye S; Casrouge A; Dorival C; Barthe Y; Fontaine H; Hézode C; Mottez E; Bronowicki JP; Carrat F; Theodorou I; Abel L; Gayat E; Fontanet A; Pol S; Albert ML;
    Liver Int; 2015 Jul; 35(7):1833-44. PubMed ID: 25556540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues.
    Brown NA
    Expert Opin Investig Drugs; 2009 Jun; 18(6):709-25. PubMed ID: 19426125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus.
    Kwong AD; Kauffman RS; Hurter P; Mueller P
    Nat Biotechnol; 2011 Nov; 29(11):993-1003. PubMed ID: 22068541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HCV antiviral resistance: the impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase.
    Tomei L; Altamura S; Paonessa G; De Francesco R; Migliaccio G
    Antivir Chem Chemother; 2005; 16(4):225-45. PubMed ID: 16130521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage.
    Devogelaere B; Berke JM; Vijgen L; Dehertogh P; Fransen E; Cleiren E; van der Helm L; Nyanguile O; Tahri A; Amssoms K; Lenz O; Cummings MD; Clayton RF; Vendeville S; Raboisson P; Simmen KA; Fanning GC; Lin TI
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4676-84. PubMed ID: 22710121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TMC-435, an NS3/4A protease inhibitor for the treatment of HCV infection.
    Tsantrizos YS
    Curr Opin Investig Drugs; 2009 Aug; 10(8):871-81. PubMed ID: 19649931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging therapeutic options for the management of hepatitis C infection.
    Thompson JR
    World J Gastroenterol; 2014 Jun; 20(23):7079-88. PubMed ID: 24966581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of chronic hepatitis C: anticipated impact of resistance in patients treated with protease inhibitors.
    Kronenberger B; Zeuzem S
    Curr Gastroenterol Rep; 2009 Feb; 11(1):15-21. PubMed ID: 19166654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.